Prashant Kumar Over the years, the FDA has published several highly targeted series of iterations on formal PDUFA interactions, beginning with foundational frameworks under FDAMA in 2000, progressing through major updates in 2017 and 2018, and evolving into draft revisions in late 2023. The latest guidance released this week discusses important procedural and logistical preferences of the … Read more
Imagine scrolling through a slick betting app, placing a quick wager on an Oscar winner, and then sliding over to bet on whether a childhood cancer drug will pass its final clinical trial. This isn’t a speculative dystopian concept; it is the current reality offered by platforms like Kalshi and Polymarket, which now allow users … Read more
Enrolling patients in clinical trials has long been one of the steepest operational hurdles in medical innovation. For years, researchers have debated whether financial compensation serves as a necessary driver for recruitment or an unethical bribe that skews participant motivation. A recent study published in JAMA Internal Medicine provides crucial clarity on this long-standing dilemma. The data reveals … Read more
When senior FDA leadership published “America Must Address Early Clinical Development” on the official FDA Voices blog, industry stakeholders immediately take notice. However, beneath the bold rhetoric lies a familiar structural tension that has plagued recent regulatory communications: the conflation of executive vision with enforceable policy. Outlining an ambitious “Expedited IND Pilot” utilizing Qualified Research Institutions (QRIs) and rolling submissions, the agency framed the … Read more
Imagine the sinking feeling of receiving a notification from your customs broker that your multi-million-dollar food shipment is officially detained at the port. You have buyers waiting on scheduled store delivery windows, warehousing demurrage charges piling up daily, and perishable goods slowly losing market value in a shipping container. For hundreds of U.S. food importers … Read more
For decades, rigid and boilerplate eligibility criteria have turned cancer clinical trials into exclusive clubs, leaving vast segments of real-world patients stranded on the outside. By routinely excluding individuals with minor laboratory anomalies, mild performance deficits, or complex medication regimens, trial sponsors have inadvertently compromised both subject accrual and the generalizability of study results. Recognizing … Read more
Navigating the regulatory clearance process for high-risk medical devices within the Center for Biologics Evaluation and Research (CBER) extends beyond securing an approval or denial order. Once a decision is rendered, regulatory affairs professionals must oversee the post-action administrative workflows that dictate public transparency. CBER’s Standard Operating Policy and Procedure (SOPP) 8795 establishes the internal mechanisms governing public … Read more
Financial conflict of interest in medical research is a topic that instantly draws headlines, skepticism, and heated academic debates. A recent study published in JAMA Network Open reignited this fire by pointing out that nearly 90% of industry-funded trials report conclusions favoring their corporate sponsors. To many observers, that statistic sounds like smoking-gun evidence that commercial money corrupts scientific … Read more
Bringing a molecule like psilocybin or MDMA to the commercial market is unlike any traditional drug development journey. In its guidance document, the FDA is proving a long-awaited regulatory map to describe how developing these drugs mirrors conventional drug development, and where it chart-starts entirely new territory. At their core, psychedelic drug programs are not exempt from the golden standards of modern medicine. The FDA makes it clear that … Read more
Navigating the labyrinth of FDA regulations often feels like learning a highly specialized dialect of a language you only half-understand. With the release of the July 2026 guidance on formal meetings for Over-the-Counter (OTC) monograph drugs, the agency has introduced a brand-new vocabulary of Type X, Y, and Z meetings. While these terms might sound like characters in an … Read more
